Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics June 2, 2026
FDA Accepts NDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC with Priority Review & PDUFA target action date of Nov 27, 2026 June 2, 2026
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines June 2, 2026
Positive Recommendation from DSMB for Ph 3 Study of Bria-IMT + CPI in Metastatic Breast Cancer June 2, 2026
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084) for Certain Patients with 1L Metastatic KRAS G12C-Mutant NSCLC June 2, 2026
NETRIS Pharma Secures €7.25M in Horizon Europe Funding to Advance Ph 2b Clinical Trial in Head and Neck Cancer June 2, 2026
Adcendo ApS Announces Collaboration with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA in Ph 1b Study in Patients with Advanced Solid Tumors June 2, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA in Metastatic CRPC June 2, 2026
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development June 2, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Gen Oncology Therapies and $215M Concurrent Private Placement June 2, 2026
Ph 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes did not meet predefined threshold to support further development June 2, 2026
Primary Endpoints Met in Final Analysis of Ph 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC June 2, 2026
Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development Successfully Completed June 2, 2026
FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data June 2, 2026
CHMP Positive Opinion for Trodelvy in 1L Metastatic TNBC for Patients Not Candidates for PD-(L)1 Inhibitors June 2, 2026
FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat indolent non-Hodgkin lymphoma June 2, 2026
